Trial Profile
An Open-Label, Multicenter, Dose-Escalation Phase IB Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonist) in Combination With Atezolizumab (Anti PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Selicrelumab (Primary) ; Selicrelumab (Primary)
- Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 03 Nov 2020 This trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
- 11 Dec 2019 Status changed from active, no longer recruiting to completed.
- 05 Dec 2019 This trial has been completed in Spain, according to European Clinical Trials Database.